预约演示

更新于：2026-10-23

Chlorothiazide

氯噻嗪

更新于：2026-10-23

概要

基本信息

药物类型

小分子化药

别名

6-Chloro-1,1-dioxo-1,2-dihydro-1lambda*6*-benzo[1,2,4]thiadiazine-7-sulfonic acid amide、6-chloro-7-sulfamoyl-2H-1,2,4-benzothiadiazine 1,1-dioxide、Chlorothiazid

+ [6]

靶点

NCC

作用方式

抑制剂

作用机制

NCC抑制剂(噻嗪类敏感氯化钠协同转运蛋白抑制剂)

治疗领域

心血管疾病消化系统疾病泌尿生殖系统疾病+ [1]

在研适应症-

非在研适应症

水肿肾小球肾炎心脏衰竭+ [5]

原研机构

Novartis Pharma AG

在研机构-

非在研机构

Salix Pharmaceuticals, Inc.

Salix Pharma

权益机构-

最高研发阶段撤市

首次获批日期

美国 (1961-10-06),

水肿肾小球肾炎心脏衰竭+ [5]

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

分子式C7H6ClN3O4S2

InChIKeyJBMKAUGHUNFTOL-UHFFFAOYSA-N

CAS号58-94-6

关联

项与氯噻嗪相关的临床试验

NCT07568574

/ Enrolling by invitationN/AIIT

Impact of Medically Supervised Performance-Enhancing Substances (PES) on Elite Athletes: A Hybrid Design in a Real-World Setting

Objectives:
The primary objective is to assess the safety and tolerability of medical drugs with the potential to enhance performance (PES) in professional athletes over a 5.5 year period, encompassing a 25-week PES Exposure period and 5 year long term follow-up of period comprehensive health and safety monitoring. The secondary objective is to evaluate the impact of PES on athletic performance through validated sport specific and clinical assessments.
Methods:
This prospective hybrid design study will enrol 60 adult participants, divided into two groups. The first group will receive performance-enhancing substances (PES) directly through the study, administered as Investigational Medicinal Products (IMPs) under comprehensive medical supervision for up to 25 weeks. The second group will include natural athletes and those already using PES prescribed by their own doctors. All substances used in this study are medically approved by national regulatory agencies (e.g., FDA, MHRA, EMA, EDE, etc.), and market authorised.
Participants undergo enrollment and baseline health and performance assessments, prior to a 25 weeks of PES exposure. During the period of PES exposure, participants undergo periodic monitoring of comprehensive physiological biomarkers alongside subjective assessments. Following the PES exposure phase, participants will complete repeat baseline health and performance assessments, followed by a titration phase and, where indicated, post-cycle therapy (PCT) to support the restoration of physiological function toward baseline. The study will conclude with a five-year longitudinal follow-up period to monitor long-term health outcomes. During this phase, participants will undergo annual assessments, including cardiac electrocardiography (ECG), echocardiography, magnetic resonance imaging (MRI), blood and urine biomarkers, routine vital signs, and quality-of-life measures. Additional imaging will include brain functional MRI (fMRI) and vital organ ultrasound at years 1, 3, and 5, with cardiac CT performed as clinically indicated. Athlete safety biomarker assessments, clinical evaluations, and adverse event reporting, will be continuously evaluated by study doctors and with additional safety oversight from a Data Safety Monitoring Board, Independent Medical Commission (a multidisciplinary panel of medical experts), and a Medical Monitor.

开始日期2026-03-12

申办/合作机构-

NCT03574857

/ Terminated临床4期IIT

Prospective Comparison of Metolazone Versus Chlorothiazide for Acute Decompensated Heart Failure With Diuretic Resistance

The primary objective of the study is to compare efficacy of metolazone and chlorothiazide as add-on therapy in patients refractory to loop diuretics with heart failure with a reduced ejection fraction (HFrEF). This will be a single-center randomized pilot study.

开始日期2018-06-01

申办/合作机构

University of Virginia

NCT02606253

/ Completed临床4期IIT

Comparison of Oral Thiazides vs Intravenous Thiazides vs Tolvaptan in Combination With Loop Diuretics for Diuretic Resistant Decompensated Heart Failure

Broad Objectives: To determine the comparative efficacy of commonly employed strategies to overcome loop diuretic resistance when added to concomitant loop diuretics in hospitalized decompensated heart failure patients with hypervolemia
Specific Aims:
1. Compare the 48-hour weight change of either intravenous chlorothiazide or oral tolvaptan compared to standard-of-care oral metolazone when combined with standardized loop diuretic dosing for diuretic resistance in decompensated heart failure
2. Compare the adverse effects of electrolyte depletion and renal function changes between intravenous chlorothiazide or oral tolvaptan compared to standard-of-care oral metolazone when combined with standardized loop diuretic dosing for diuretic resistance in acute heart failure
3. Pharmacoeconomic analysis of the direct costs of intravenous chlorothiazide or oral tolvaptan compared to standard-of-care oral metolazone when combined with standardized loop diuretic dosing for diuretic resistance in acute heart failure
The investigators will conduct a dual center, randomized, double-blind, double-dummy, parallel design trial comparing: oral metolazone, intravenous chlorothiazide, or oral tolvaptan, in combination with loop diuretics in 60 patients hospitalized for hypervolemic decompensated heart failure and displaying loop diuretic resistance.

开始日期2016-02-01

申办/合作机构

Vanderbilt University

100 项与氯噻嗪相关的临床结果

登录后查看更多信息

100 项与氯噻嗪相关的转化医学

登录后查看更多信息

100 项与氯噻嗪相关的专利（医药）

登录后查看更多信息

2,709

项与氯噻嗪相关的文献（医药）

2026-05-01·AMERICAN JOURNAL OF PERINATOLOGY

Chlorothiazide Is Associated with a Weaker Diuretic Response than Furosemide in Infants with Bronchopulmonary Dysplasia

Article

作者: Sara Bonamo DeMauro ; Nicolas P. Goldstein Novick ; Timothy D. Nelin ; Anna O’Brien ; Nicolas Bamat ; Avery W. Zierk ; David Rub ; Anna O'Brien ; Kathleen Gibbs ; Sara B. DeMauro ; Scott A. Lorch ; Heidi Morris ; Nicolas A. Bamat ; Erik A. Jensen ; Timothy Nelin ; Matthew Huber ; Avery Zierk ; David M. Rub ; Nicolas Goldstein Novick

Abstract:

This study aimed to compare the acute diuretic effect of furosemide versus chlorothiazide in preterm infants with high-grade bronchopulmonary dysplasia (BPD).We conducted a retrospective cohort study of infants with grade 2 or 3 BPD admitted to a level IV NICU between 36 and 60 weeks postmenstrual age. Novel diuretic exposures were defined as administration of furosemide or chlorothiazide without prior exposure to the same agent in the preceding 7 days. The primary outcome was the within-subject change in net fluid balance (mL/kg) in the 24 hours before and after diuretic initiation. Multivariable linear regression was performed adjusted for diuretic dosing, route, frequency, and clinical covariates.Among 300 infants contributing 136 furosemide and 215 chlorothiazide exposures, furosemide was most often dosed every 24 hours (73%) and chlorothiazide every 12 hours (90%). After covariate adjustment, furosemide was associated with a threefold greater reduction in net fluid balance compared to chlorothiazide (−32.0 vs. −10.5 mL/kg; p < 0.001). More frequent dosing (every 12 hours) was associated with greater diuretic effect than every 24-hour dosing for both agents (−22.4 vs. −11.3 mL/kg; p = 0.032). Concomitant use of both agents was common, yet the order of administration did not significantly influence fluid balance. No other clinical or biochemical characteristics were significantly associated with diuretic response.Furosemide has a significantly greater acute diuretic effect than chlorothiazide in infants with high-grade BPD. These findings may inform short-term fluid management strategies and support further investigation into optimal diuretic selection and dosing in this population.

2026-04-13·ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Engineered Biomimetic Nanoparticles With Targeted Delivery of Chlorothiazide for the Treatment of Inflammatory Bowel Disease

Article

作者: Song, Mingming ; Ou, Yurong ; Lin, Xin ; Shi, Yujie ; Wu, Qiong ; Wang, Li

ABSTRACT:

While conventional treatment strategies for inflammatory bowel disease (IBD) focus primarily on suppressing overactive immunity, there is still a lack of definitive interventions targeting key pathological mechanisms, such as intestinal barrier dysfunction, dysbiosis of the gut microbiome, and disrupted mucosal immune regulation. Using a high‐throughput drug screening platform, the present study successfully identified chlorothiazide (Chl), a lead compound with anti‐inflammatory potential, from a library of 3152 natural compounds. To further increase the bioavailability of Chl and mitigate its potential toxicity, we constructed a biomimetic delivery system based on engineered bacterial membrane‐encapsulated reactive oxygen species (ROS)‐responsive biomimetic nanoparticles (CHM NPs). This delivery system achieved targeted accumulation in inflamed colonic tissue in a mouse model of acute colitis and effectively facilitated the restoration of epithelial barrier function. Moreover, CHM NPs significantly altered the gut microbiome, increasing overall microbial abundance and diversity while increasing the abundance of gut Lactobacillus , which plays a crucial role in maintaining gut microecological homeostasis. We systematically elucidated the multifaceted mechanisms by which CHM NPs regulate gut homeostasis, remodel the microbial composition, and modulate innate immunity. These findings provide novel theoretical foundations and potential intervention strategies for the treatment of IBD and other related inflammatory conditions.

2026-03-01·JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Loop Diuretic Dose Intensification versus Adjuvant Thiazide for Diuretic Resistance in Acute Heart Failure

Article

作者: Shilpak, Michael G. ; Ramos-Mastache, Daniela ; Estrella, Michelle M. ; Cox, Zachary L. ; Ivey-Miranda, Juan B. ; Welling, Paul ; Maulion, Christopher ; Rao, Veena S. ; Moreno-Villagomez, Julieta ; Testani, Jeffrey M. ; Forbush, Biff ; Turner, Jeffrey ; Bellumkonda, Lavanya ; Ellison, David H. ; Wilcox, Christopher S. ; Wilson, F. Perry

Key Points:

Adjuvant thiazide improved diuretic response more than loop dose increase in patients with acute heart failure and diuretic resistance.The underlying diuretic resistance mechanism did not identify preferential response to either diuretic escalation strategy.

Background:

The optimal therapy for loop diuretic resistance may differ if caused by resistance at the site of action in the loop of Henle (diuretic resistance at the loop of Henle [DR-Loop]) versus compensatory distal reabsorption (diuretic resistance due to distal sodium reabsorption [DR-Distal]). This study primarily aimed to compare diuretic strategies and explore whether targeting the underlying diuretic resistance mechanism could optimize diuretic response.

Methods:

Patients hospitalized with heart failure and diuretic resistance (6-hour cumulative natriuresis <100 mmol after intravenous [IV] loop diuretic) were randomized 1:1 to ( 1 ) 2.5× IV loop dose intensification or ( 2 ) IV chlorothiazide addition to the same loop diuretic. The primary trial outcome was the increase in 6-hour natriuresis between strategies. Exploratory analyses of diuretic resistance mechanism were performed. Diuretic resistance mechanisms were categorized using the fractional excretion of lithium (FE Li ), a metric evaluating sodium exit from the loop of Henle. DR-Loop was defined as a loop diuretic–induced increase in FE Li below the median and DR-Distal as an increase in FE Li above the median at the screening visit.

Results:

Patients (mean age 68±12 years, 40% women) were randomized to loop dose intensification ( n =51) or adjuvant thiazide ( n =52). The primary outcome of increase in 6-hour natriuresis improved significantly with both strategies. However, chlorothiazide addition produced a significantly larger improvement in 6-hour natriuresis (107 mmol increase [95% confidence interval (CI), 81 to 132]) compared with loop augmentation (49 mmol increase [95% CI, 31 to 66]; treatment effect 58 mmol [95% CI, 27 to 89]; P < 0.001). Paradoxically, loop intensification augmented natriuresis less in patients with DR-Loop compared with DR-Distal (27±39 versus 75±77 mmol, respectively, P = 0.004), and adjuvant thiazide did not increase natriuresis more in patients with DR-Distal versus DR-Loop (92±71 versus 105±86 mmol, respectively, P = 0.54).

Conclusions:

Strategies of loop dose intensification and adjuvant thiazide both improved diuretic response, with a significantly larger augmentation of natriuresis with adjuvant thiazide. The underlying diuretic resistance mechanism did not identify a preferential response to either therapy.

Clinical Trial registry name and registration number::

ClinicalTrials.gov, Diagnosing and Targeting Mechanisms of Diuretic Resistance in Heart Failure NCT02546583.

项与氯噻嗪相关的新闻（医药）

2026-09-30

·赛柏蓝

第13批集采盯上10个降压药

编者按：本文来自米内网，作者玲珑；赛柏蓝转载，编辑晓琳在国采、国谈等政策驱动下，高血压化药500亿市场波澜起伏。 01 第13批国采盯上10个品种石四药、复星蓄力截至9月24日，国内已有127个高血压化药有企业过评或视同过评。其中，21个品种过评企业数均达20家及以上，苯磺酸氨氯地平片以67家企业领跑，沙库巴曲缬沙坦钠片以43家企业紧接其后。从企业过评情况看，华海药业、石家庄四药、华润医药、上海医药、复星医药、国药集团等10余家集团过评品种数均达10个及以上，其中华海药业以31个品种领跑，石家庄四药、华润医药以23个品种并列第二。作为国内临床用药金额领先的品类，高血压化药是集采的重点对象。在国家开展的十一批十二轮化药集采中，高血压化药分别有7个、5个、2个、4个、3个、4个、5个、3个、4个、1个、9个品种被纳入其中，合计47个品种（以通用名计）。除已纳入国采品种，目前还有10个高血压化药满足入围门槛，符合申报资格企业数达7家及以上，包括5个口服常释剂型、5个注射剂。暂未纳入国采且已满足充分竞争条件的高血压化药注：过评企业数以集团计，销售额低于1亿元用*代替从2025年中国公立医疗机构终端销售额看，坎地沙坦酯氢氯噻嗪口服常释剂型超过3亿元，螺内酯口服常释剂型、呋塞米口服常释剂型超过2亿元，硝普钠注射剂、利奥西呱口服常释剂型、地尔硫卓注射剂超过1亿元。从企业看，石家庄四药以5个过评品种领跑，复星医药以4个过评品种紧接其后，华夏生生以3个过评品种排位第三；此外，华润医药、迪赛诺、瑞尔医药、普洛药业、华海药业、朗欧医药、南京泽恒医药、浙江亚太药业等均有2个过评品种在列等。 02 高血压化药市场回暖国谈药大涨80% 2025年中国公立医疗机构终端高血压化药市场迎来回暖，销售额超过500亿元，同比增长约7%；2026年上半年超过270亿元，同比增长超10%。近年来中国公立医疗机构终端高血压化药销售情况（单位：万元）从厂家排名看，2026年上半年高血压化药TOP20一级集团合计市场份额约56%。诺华、拜耳、晖致、信立泰、华海药业依次位列前五，其中信立泰同比大涨34.08%，较2025年提升2个位次；从增长情况看，拜耳、信立泰、正大制药均涨逾20%。 2026H1中国公立医疗机构终端高血压化药集团TOP5 从产品排名看，2026年上半年高血压化药产品TOP20合计市场份额超过68%。其中，沙库巴曲缬沙坦钠片以近40亿元稳居首位，硝苯地平控释片以近20亿元紧接其后，苯磺酸氨氯地平片以超15亿元排位第三；琥珀酸美托洛尔缓释片、厄贝沙坦氢氯噻嗪片、苯磺酸左氨氯地平片依次位列第四至第六，销售额均超过10亿元。 2026H1中国公立医疗机构终端高血压化药产品TOP20 20个产品中，有17个已被纳入国采，其中4+7集采及扩围品种有4个，第12批、第4批国采品种各有3个，第7批、第8批国采品种各有2个等。包括厄贝沙坦片、替米沙坦片2款新增纳入2026版国家基药品种；非奈利酮片为国谈药（2025版），且10mg规格新增纳入新版国家基药；阿利沙坦酯片、氨氯地平贝那普利片(Ⅱ)均为独家品种，其中阿利沙坦酯片为国产1类新药。从销售额增长情况看，18个产品呈正增长态势，其中有13个涨逾10%，非奈利酮片以79.57%的增速领跑，沙库巴曲缬沙坦钠片、厄贝沙坦氢氯噻嗪片、甲磺酸多沙唑嗪缓释片、托伐普坦片均涨逾20%。本期素材组图片来源：https://unsplash.com/s/photos/ END

带量采购

2026-09-28

·微信

第13批集采盯上10个降压药！潜力品种大涨80%，1类新药或参战，500亿市场波澜起伏

精彩内容在国采、国谈等政策驱动下，高血压化药500亿市场波澜起伏。高血压化药市场回暖！国谈药大涨80% 经过连续三年下挫后，2025年中国公立医疗机构终端（统计范围详见本文末）高血压化药市场迎来回暖，销售额超过500亿元，同比增长约7%；2026年上半年超过270亿元，同比增长超10%。近年来中国公立医疗机构终端高血压化药销售情况（单位：万元）来源：米内网中国公立医疗机构药品终端竞争格局从厂家排名看，2026年上半年高血压化药TOP20一级集团合计市场份额约56%，诺华、拜耳、晖致、信立泰、华海药业依次位列前五，其中信立泰同比大涨34.08%，较2025年提升2个位次；从增长情况看，拜耳、信立泰、正大制药均涨逾20%。 2026H1中国公立医疗机构终端高血压化药集团TOP5 来源：米内网中国公立医疗机构药品终端竞争格局从产品排名看，2026年上半年高血压化药产品TOP20合计市场份额超过68%。其中，沙库巴曲缬沙坦钠片以近40亿元稳居首位，硝苯地平控释片以近20亿元紧接其后，苯磺酸氨氯地平片以超15亿元排位第三；琥珀酸美托洛尔缓释片、厄贝沙坦氢氯噻嗪片、苯磺酸左氨氯地平片依次位列第四至第六，销售额均超过10亿元。 2026H1中国公立医疗机构终端高血压化药产品TOP20 来源：米内网综合数据库 20个产品中，有17个已被纳入国采，其中4+7集采及扩围品种有4个，第12批、第4批国采品种各有3个，第7批、第8批国采品种各有2个等，包括厄贝沙坦片、替米沙坦片2款新增纳入2026版国家基药品种；非奈利酮片为国谈药（2025版），且10mg规格新增纳入新版国家基药；阿利沙坦酯片、氨氯地平贝那普利片(Ⅱ)均为独家品种，其中阿利沙坦酯片为国产1类新药。从销售额增长情况看，18个产品呈正增长态势，其中有13个涨逾10%，非奈利酮片以79.57%的增速领跑，沙库巴曲缬沙坦钠片、厄贝沙坦氢氯噻嗪片、甲磺酸多沙唑嗪缓释片、托伐普坦片均涨逾20%。第13批国采盯上10个品种，石四药、复星蓄力米内网数据显示，截至9月24日，国内已有127个高血压化药有企业过评或视同过评。其中，21个品种过评企业数均达20家及以上，苯磺酸氨氯地平片以67家企业领跑，沙库巴曲缬沙坦钠片以43家企业紧接其后。从企业过评情况看，华海药业、石家庄四药、华润医药、上海医药、复星医药、国药集团等10余家集团过评品种数均达10个及以上，其中华海药业以31个品种领跑，石家庄四药、华润医药以23个品种并列第二。作为国内临床用药金额领先的品类，高血压化药是集采的重点对象。在国家开展的十一批十二轮化药集采中，高血压化药分别有7个、5个、2个、4个、3个、4个、5个、3个、4个、1个、9个品种被纳入其中，合计47个品种（以通用名计）。除了已纳入国采品种，目前还有10个高血压化药满足入围门槛，符合申报资格企业数达7家及以上，包括5个口服常释剂型、5个注射剂。暂未纳入国采且已满足充分竞争条件的高血压化药注：过评企业数以集团计，销售额低于1亿元用*代替来源：米内网综合数据库从2025年中国公立医疗机构终端销售额看，坎地沙坦酯氢氯噻嗪口服常释剂型超过3亿元，螺内酯口服常释剂型、呋塞米口服常释剂型超过2亿元，硝普钠注射剂、利奥西呱口服常释剂型、地尔硫卓注射剂超过1亿元。从企业看，石家庄四药以5个过评品种领跑，复星医药以4个过评品种紧接其后，华夏生生以3个过评品种排位第三；此外，华润医药、迪赛诺、瑞尔医药、普洛药业、华海药业、朗欧医药、南京泽恒医药、浙江亚太药业等均有2个过评品种在列等。独家品种霸屏！13个品种有望参与2026国谈在2025版国家医保中，以谈判竞价纳入的高血压化药有9个。米内网数据显示，近年来中国公立医疗机构终端国谈高血压化药市场快速放量，2025年销售额超过18亿元，同比增长超100%；2026年上半年超过14亿元，同比增长超80%。近年来中国公立医疗机构终端国谈高血压化药销售情况（单位：万元）来源：米内网中国公立医疗机构药品终端竞争格局在2026年国家医保目录调整中，有13个高血压化药（7个独家品种、6个非独家品种）通过目录外形式审查，有望参与谈判/竞价。有望参与2026年国谈的高血压化药来源：国家医保局、米内网数据库 7个为独家品种。其中，苹果酸司妥吉仑片为上海医药开发的一款国产1类新药，属于新一代口服非肽类小分子直接肾素抑制剂(DRI)，开启了高血压“源头治疗”新纪元；默沙东的注射用索特西普为全球首个激活素信号传导抑制剂(ASI)，针对的是肺动脉高压(PAH)这种罕见且通常迅速进展的疾病。 6个非独家品种中，马来酸依那普利口服溶液、氯维地平乳状注射液分别纳入《第三批鼓励研发申报儿童药品清单》、第二批《鼓励仿制药目录》，目前均有5家企业拥有生产批文，且均已视同过评。资料来源：米内网数据库、国家医保局等注：米内网《中国公立医疗机构药品终端竞争格局》，统计范围：中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院，不含民营医院、私人诊所、村卫生室；上述销售额以产品在终端的平均零售价计算。数据统计截至9月24日，如有疏漏，欢迎指正！信息来源：米内网往期推荐 ! 免责声明 “汇聚南药”公众号所转载文章来源于其他公众号平台，主要目的在于分享行业相关知识，传递当前最新资讯。图片、文章版权均属于原作者所有，如有侵权，请在留言栏及时告知，我们会在24小时内删除相关信息。本平台不对转载文章的观点负责，文章所包含内容的准确性、可靠性或完整性提供任何明示暗示的保证。喜欢的点个“看一看”和"喜欢"吧不然微信推送规则改变，有可能每天都会错过我们哦~

2026-09-28

·米内网

第13批集采盯上10个降压药！潜力品种大涨80%，1类新药或参战，500亿市场波澜起伏

精彩内容在国采、国谈等政策驱动下，高血压化药500亿市场波澜起伏。高血压化药市场回暖！国谈药大涨80% 经过连续三年下挫后，2025年中国公立医疗机构终端（统计范围详见本文末）高血压化药市场迎来回暖，销售额超过500亿元，同比增长约7%；2026年上半年超过270亿元，同比增长超10%。近年来中国公立医疗机构终端高血压化药销售情况（单位：万元）来源：米内网中国公立医疗机构药品终端竞争格局从厂家排名看，2026年上半年高血压化药TOP20一级集团合计市场份额约56%，诺华、拜耳、晖致、信立泰、华海药业依次位列前五，其中信立泰同比大涨34.08%，较2025年提升2个位次；从增长情况看，拜耳、信立泰、正大制药均涨逾20%。 2026H1中国公立医疗机构终端高血压化药集团TOP5 来源：米内网中国公立医疗机构药品终端竞争格局从产品排名看，2026年上半年高血压化药产品TOP20合计市场份额超过68%。其中，沙库巴曲缬沙坦钠片以近40亿元稳居首位，硝苯地平控释片以近20亿元紧接其后，苯磺酸氨氯地平片以超15亿元排位第三；琥珀酸美托洛尔缓释片、厄贝沙坦氢氯噻嗪片、苯磺酸左氨氯地平片依次位列第四至第六，销售额均超过10亿元。 2026H1中国公立医疗机构终端高血压化药产品TOP20 来源：米内网综合数据库 20个产品中，有17个已被纳入国采，其中4+7集采及扩围品种有4个，第12批、第4批国采品种各有3个，第7批、第8批国采品种各有2个等，包括厄贝沙坦片、替米沙坦片2款新增纳入2026版国家基药品种；非奈利酮片为国谈药（2025版），且10mg规格新增纳入新版国家基药；阿利沙坦酯片、氨氯地平贝那普利片(Ⅱ)均为独家品种，其中阿利沙坦酯片为国产1类新药。从销售额增长情况看，18个产品呈正增长态势，其中有13个涨逾10%，非奈利酮片以79.57%的增速领跑，沙库巴曲缬沙坦钠片、厄贝沙坦氢氯噻嗪片、甲磺酸多沙唑嗪缓释片、托伐普坦片均涨逾20%。第13批国采盯上10个品种，石四药、复星蓄力米内网数据显示，截至9月24日，国内已有127个高血压化药有企业过评或视同过评。其中，21个品种过评企业数均达20家及以上，苯磺酸氨氯地平片以67家企业领跑，沙库巴曲缬沙坦钠片以43家企业紧接其后。从企业过评情况看，华海药业、石家庄四药、华润医药、上海医药、复星医药、国药集团等10余家集团过评品种数均达10个及以上，其中华海药业以31个品种领跑，石家庄四药、华润医药以23个品种并列第二。作为国内临床用药金额领先的品类，高血压化药是集采的重点对象。在国家开展的十一批十二轮化药集采中，高血压化药分别有7个、5个、2个、4个、3个、4个、5个、3个、4个、1个、9个品种被纳入其中，合计47个品种（以通用名计）。除了已纳入国采品种，目前还有10个高血压化药满足入围门槛，符合申报资格企业数达7家及以上，包括5个口服常释剂型、5个注射剂。暂未纳入国采且已满足充分竞争条件的高血压化药注：过评企业数以集团计，销售额低于1亿元用*代替来源：米内网综合数据库从2025年中国公立医疗机构终端销售额看，坎地沙坦酯氢氯噻嗪口服常释剂型超过3亿元，螺内酯口服常释剂型、呋塞米口服常释剂型超过2亿元，硝普钠注射剂、利奥西呱口服常释剂型、地尔硫卓注射剂超过1亿元。从企业看，石家庄四药以5个过评品种领跑，复星医药以4个过评品种紧接其后，华夏生生以3个过评品种排位第三；此外，华润医药、迪赛诺、瑞尔医药、普洛药业、华海药业、朗欧医药、南京泽恒医药、浙江亚太药业等均有2个过评品种在列等。独家品种霸屏！13个品种有望参与2026国谈在2025版国家医保中，以谈判竞价纳入的高血压化药有9个。米内网数据显示，近年来中国公立医疗机构终端国谈高血压化药市场快速放量，2025年销售额超过18亿元，同比增长超100%；2026年上半年超过14亿元，同比增长超80%。近年来中国公立医疗机构终端国谈高血压化药销售情况（单位：万元）来源：米内网中国公立医疗机构药品终端竞争格局在2026年国家医保目录调整中，有13个高血压化药（7个独家品种、6个非独家品种）通过目录外形式审查，有望参与谈判/竞价。有望参与2026年国谈的高血压化药来源：国家医保局、米内网数据库 7个为独家品种。其中，苹果酸司妥吉仑片为上海医药开发的一款国产1类新药，属于新一代口服非肽类小分子直接肾素抑制剂(DRI)，开启了高血压“源头治疗”新纪元；默沙东的注射用索特西普为全球首个激活素信号传导抑制剂(ASI)，针对的是肺动脉高压(PAH)这种罕见且通常迅速进展的疾病。 6个非独家品种中，马来酸依那普利口服溶液、氯维地平乳状注射液分别纳入《第三批鼓励研发申报儿童药品清单》、第二批《鼓励仿制药目录》，目前均有5家企业拥有生产批文，且均已视同过评。资料来源：米内网数据库、国家医保局等注：米内网《中国公立医疗机构药品终端竞争格局》，统计范围：中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院，不含民营医院、私人诊所、村卫生室；上述销售额以产品在终端的平均零售价计算。数据统计截至9月24日，如有疏漏，欢迎指正！免责声明：本文仅作医药信息传播分享，并不构成投资或决策建议。本文为原创稿件，转载文章或引用数据请注明来源和作者，否则将追究侵权责任。

100 项与氯噻嗪相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00519	氯噻嗪	C03AA04	DB00880

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
水肿	美国	Salix Pharma	1961-10-06
水肿	美国	Salix Pharmaceuticals, Inc.	1961-10-06
肾小球肾炎	美国	Salix Pharmaceuticals, Inc.	1961-10-06
肾小球肾炎	美国	Salix Pharma	1961-10-06
心脏衰竭	美国	Salix Pharmaceuticals, Inc.	1961-10-06
心脏衰竭	美国	Salix Pharma	1961-10-06
高血压	美国	Salix Pharma	1961-10-06
高血压	美国	Salix Pharmaceuticals, Inc.	1961-10-06
终末期肾脏病	美国	Salix Pharma	1961-10-06
终末期肾脏病	美国	Salix Pharmaceuticals, Inc.	1961-10-06
肝硬化	美国	Salix Pharmaceuticals, Inc.	1961-10-06
肝硬化	美国	Salix Pharma	1961-10-06
肾病综合征	美国	Salix Pharmaceuticals, Inc.	1961-10-06
肾病综合征	美国	Salix Pharma	1961-10-06
肾功能不全	美国	Salix Pharma	1961-10-06
肾功能不全	美国	Salix Pharmaceuticals, Inc.	1961-10-06

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02546583 (Pubmed \| J Am Soc Nephrol)	临床1期	心脏衰竭	103	Loop Diuretic Dose Intensification	鹽鬱獵鑰艱選遞鏇築範(網壓鏇網糧觸遞鬱積網) = 膚膚餘齋選衊鑰憲壓觸淵鏇憲遞願壓夢鬱艱願 (鏇淵餘糧鏇鹽範廠襯艱, 31 ~ 66) 更多	积极	2025-09-12
				Adjuvant Thiazide	鹽鬱獵鑰艱選遞鏇築範(網壓鏇網糧觸遞鬱積網) = 鏇觸鏇簾獵襯選積淵壓淵鏇憲遞願壓夢鬱艱願 (鏇淵餘糧鏇鹽範廠襯艱, 81 ~ 132) 更多
NCT02606253 (3T, Pubmed \| JACC Heart Fail)	临床4期	心脏衰竭 \| 急性失代偿性心力衰竭	60	Oral metolazone	醖選簾鏇網糧鹽簾願窪(憲網廠構遞壓鏇願膚獵) = 壓衊鹹齋醖廠糧壓築鬱範構願襯窪觸願壓遞糧 (網壓衊繭襯積顧窪膚餘 ) 更多	-	2020-03-01
				IV chlorothiazide	醖選簾鏇網糧鹽簾願窪(憲網廠構遞壓鏇願膚獵) = 淵顧壓齋壓鑰糧積廠製範構願襯窪觸願壓遞糧 (網壓衊繭襯積顧窪膚餘, 1.2 [-2.9 ~ 0.6]) 更多
NCT02606253 (3T, CTgov)	临床4期	心脏衰竭 \| 急性失代偿性心力衰竭	60	Metolazone (Metolazone)	範艱壓淵襯蓋鏇鏇範顧(蓋範遞遞襯蓋齋鑰廠鬱) = 憲網壓築製網餘積積壓鬱範鹽廠淵願網醖壓鹽 (築鹹鏇壓餘廠鏇構積顧, 2.7) 更多	-	2019-11-08
				Chlorothiazide (Chlorothiazide)	範艱壓淵襯蓋鏇鏇範顧(蓋範遞遞襯蓋齋鑰廠鬱) = 獵鹹築齋範廠鏇廠鹹艱鬱範鹽廠淵願網醖壓鹽 (築鹹鏇壓餘廠鏇構積顧, 2.7) 更多